COMP <GO>
RGEN vs MRK // EV/EBITDA & P/E VALUATION
Repligen Corporation (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: RGEN 4
— MRK 11
▲ EV/EBITDA & P/E VALUATION LEADER: MRK
LAST: $176.94 (-6.20%) • MKT CAP: $10.69B
valuation
95.0x
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
valuation
15.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RGEN VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RGEN | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 88.20% | 74.80% | +13.40 | RGEN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 2.30% | 20.70% | -18.40 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 95.0x | 15.3x | +79.70 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 0.88% | 3.42% | -2.54 | MRK | /fcf-yield <GO> |
| Operating Margin | 1.80% | 34.30% | -32.50 | MRK | /operating-margins <GO> |
| Net Profit Margin | 1.60% | 28.10% | -26.50 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | -3.30% | 1.30% | -4.60 | MRK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 9.31 | 5.19 | +4.12 | RGEN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | RGEN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.00% | 6.60% | +0.40 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.7 | 56.9 | -8.20 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.04 | 0.92 | +0.12 | RGEN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 140.0x | 18.4x | +121.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.69B | $361.02B | -$350.33B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RGEN REV | MRK REV | RGEN GROSS % | MRK GROSS % | RGEN FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $65.01B | — | 74.8% | $93.9M | $12.36B |
| FY 2024 | $0 | $64.17B | — | 76.3% | $149.7M | $18.10B |
| FY 2023 | $0 | $60.12B | — | 44.0% | $113.9M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RGEN // BETA 1.04
MRK // BETA 0.92